{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:43:07Z","timestamp":1791916987364,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program key projects","doi-asserted-by":"publisher","award":["201803010012"],"award-info":[{"award-number":["201803010012"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.thromres.2022.02.021","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T18:55:03Z","timestamp":1645901703000},"page":"128-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["HMGB1 is increased in patients with immune thrombocytopenia and negatively associates with Tregs"],"prefix":"10.1016","volume":"213","author":[{"given":"Guoyang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danian","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.thromres.2022.02.021_bb0005","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia[J]","volume":"381","author":"Cooper","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.thromres.2022.02.021_bb0010","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ajh.20992","article-title":"Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura[J]","volume":"83","author":"Mcmillan","year":"2008","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.thromres.2022.02.021_bb0015","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood-2016-03-603365","article-title":"How I treat refractory immune thrombocytopenia[J]","volume":"128","author":"Cuker","year":"2016","journal-title":"Blood"},{"issue":"7040","key":"10.1016\/j.thromres.2022.02.021_bb0020","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(58)90057-6","article-title":"The treatment of idiopathic thrombocytopenic purpura; a review of ninety-three cases[J]","volume":"2","author":"Watson-Williams","year":"1958","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.thromres.2022.02.021_bb0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1160\/TH07-08-0513","article-title":"Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management[J]","volume":"99","author":"Stasi","year":"2008","journal-title":"Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2022.02.021_bb0030","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.hoc.2009.08.008","article-title":"Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production[J]","volume":"23","author":"Mcmillan","year":"2009","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"2","key":"10.1016\/j.thromres.2022.02.021_bb0035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/labinvest.2014.142","article-title":"Inactivation of notch signaling reverses the Th17\/Treg imbalance in cells from patients with immune thrombocytopenia[J]","volume":"95","author":"Yu","year":"2015","journal-title":"Lab. Investig."},{"issue":"11","key":"10.1016\/j.thromres.2022.02.021_bb0040","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17\u2013producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages[J]","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.thromres.2022.02.021_bb0045","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3324\/haematol.2009.007823","article-title":"Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura[J]","volume":"94","author":"Zhang","year":"2009","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.thromres.2022.02.021_bb0050","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.thromres.2013.04.025","article-title":"Involvement of levels of toll like receptor-4 in monocytes, CD4+ T-lymphocyte subsets, and cytokines in patients with immune thrombocytopenic purpura[J]","volume":"132","author":"Liu","year":"2013","journal-title":"Thromb. Res."},{"issue":"12","key":"10.1016\/j.thromres.2022.02.021_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050909","article-title":"The ratio of Treg\/Th17 cells correlates with the disease activity of primary immune thrombocytopenia[J]","volume":"7","author":"Ji","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.thromres.2022.02.021_bb0060","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MOH.0000000000000612","article-title":"An update on the pathophysiology of immune thrombocytopenia[J]","volume":"27","author":"Semple","year":"2020","journal-title":"Curr. Opin. Hematol."},{"issue":"2","key":"10.1016\/j.thromres.2022.02.021_bb0065","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/jcm6020016","article-title":"Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)[J]","volume":"6","author":"Zufferey","year":"2017","journal-title":"J. Clin. Med."},{"issue":"9","key":"10.1016\/j.thromres.2022.02.021_bb0070","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00277-016-2738-3","article-title":"Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children[J]","volume":"95","author":"Ahmed","year":"2016","journal-title":"Ann. Hematol."},{"issue":"10","key":"10.1016\/j.thromres.2022.02.021_bb0075","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.exphem.2016.07.004","article-title":"The spleen dictates platelet destruction, anti-platelet antibody production, and lymphocyte distribution patterns in a murine model of immune thrombocytopenia[J]","volume":"44","author":"Aslam","year":"2016","journal-title":"Exp. Hematol."},{"issue":"1","key":"10.1016\/j.thromres.2022.02.021_bb0080","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1432-1033.1973.tb03026.x","article-title":"A new group of chromatin-associated proteins with a high content of acidic and basic amino acids[J]","volume":"38","author":"Goodwin","year":"1973","journal-title":"Eur. J. Biochem."},{"issue":"Suppl 1","key":"10.1016\/j.thromres.2022.02.021_bb0085","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.2119\/molmed.2015.00087","article-title":"High mobility group box protein 1 (HMGB1): the prototypical endogenous danger molecule[J]","volume":"21","author":"Yang","year":"2015","journal-title":"Mol. Med."},{"issue":"2","key":"10.1016\/j.thromres.2022.02.021_bb0090","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/jvh.12152","article-title":"Enhanced high-mobility group box 1 (HMGB1) modulates regulatory T cells (Treg)\/T helper 17 (Th17) balance via toll-like receptor (TLR)-4-interleukin (IL)-6 pathway in patients with chronic hepatitis B[J]","volume":"21","author":"Li","year":"2014","journal-title":"J. Viral Hepat."},{"issue":"12","key":"10.1016\/j.thromres.2022.02.021_bb0095","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1097\/TP.0b013e318293b7e1","article-title":"Hmgb1-TLR4-IL-23-IL-17A axis promote ischemia-reperfusion injury in a cardiac transplantation model.[J]","volume":"95","author":"H Z","year":"2013","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.thromres.2022.02.021_bb0100","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/hep.25982","article-title":"High-mobility group box 1 (HMGB1)-toll-like receptor (TLR)4-interleukin (IL)-23-IL-17A axis in drug-induced damage-associated lethal hepatitis: interaction of gammadelta T cells with macrophages[J]","volume":"57","author":"Wang","year":"2013","journal-title":"Hepatology"},{"issue":"16","key":"10.1016\/j.thromres.2022.02.021_bb0105","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1182\/blood-2011-03-344051","article-title":"Immunologic effects of rituximab on the human spleen in immune thrombocytopenia[J]","volume":"118","author":"Audia","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.thromres.2022.02.021_bb0110","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group[J]","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.thromres.2022.02.021_bb0115","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia[J]","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv."},{"issue":"3\u20134","key":"10.1016\/j.thromres.2022.02.021_bb0120","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2119\/2006-00108.Goldstein","article-title":"Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis[J]","volume":"13","author":"Goldstein","year":"2007","journal-title":"Mol. Med."},{"issue":"2","key":"10.1016\/j.thromres.2022.02.021_bb0125","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00296-010-1636-6","article-title":"Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus[J]","volume":"32","author":"Ma","year":"2012","journal-title":"Rheumatol. Int."},{"issue":"8","key":"10.1016\/j.thromres.2022.02.021_bb0130","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00011-015-0841-x","article-title":"Role of high-mobility group box 1 protein in inflammatory bowel disease[J]","volume":"64","author":"Hu","year":"2015","journal-title":"Inflamm. Res."},{"issue":"24","key":"10.1016\/j.thromres.2022.02.021_bb0140","first-page":"10931","article-title":"Potential role and mechanism for high mobility group box1 in childhood chronic immune thrombocytopenia[J]","volume":"23","author":"Wang","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.thromres.2022.02.021_bb0150","series-title":"The multifunctional alarmin HMGB1 with roles in the pathophysiology of sepsis and cancer[J]","first-page":"443","volume":"91(7)","author":"Diener","year":"2013"},{"issue":"3","key":"10.1016\/j.thromres.2022.02.021_bb0155","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1517\/14728222.2014.863876","article-title":"Targeting HMGB1 in the treatment of sepsis[J]","volume":"18","author":"Wang","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"issue":"2","key":"10.1016\/j.thromres.2022.02.021_bb0160","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0959-437X(03)00023-6","article-title":"HMGB proteins and gene expression[J]","volume":"13","author":"Agresti","year":"2003","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"5","key":"10.1016\/j.thromres.2022.02.021_bb0165","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.4049\/jimmunol.181.5.3535","article-title":"Splenectomy protects against sepsis lethality and reduces serum HMGB1 levels[J]","volume":"181","author":"Huston","year":"2008","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.thromres.2022.02.021_bb0170","first-page":"493","article-title":"Assessment of Th17\/Treg cells and th cytokines in an improved immune thrombocytopenia mouse model[J]","volume":"22","author":"Zhang","year":"2017","journal-title":"Hematology"},{"issue":"6","key":"10.1016\/j.thromres.2022.02.021_bb0175","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/MOH.0b013e32833eaef3","article-title":"Recent progress in understanding the pathogenesis of immune thrombocytopenia[J]","volume":"17","author":"Semple","year":"2010","journal-title":"Curr. Opin. Hematol."},{"issue":"6","key":"10.1016\/j.thromres.2022.02.021_bb0180","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.humimm.2012.04.015","article-title":"Elevated profiles of Th22 cells and correlations with Th17 cells in patients with immune thrombocytopenia[J]","volume":"73","author":"Hu","year":"2012","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.thromres.2022.02.021_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/295081","article-title":"Enhanced HMGB1 expression may contribute to Th17 cells activation in rheumatoid arthritis[J]","volume":"2012","author":"Shi","year":"2012","journal-title":"Clin. Dev. Immunol."},{"issue":"6","key":"10.1016\/j.thromres.2022.02.021_bb0190","doi-asserted-by":"crossref","first-page":"737","DOI":"10.5551\/jat.31088","article-title":"HMGB1Modulates the Treg\/Th17 ratio in atherosclerotic patients[J]","volume":"23","author":"Ding","year":"2016","journal-title":"J. Atheroscler. Thromb."},{"issue":"2","key":"10.1016\/j.thromres.2022.02.021_bb0195","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.clim.2015.08.012","article-title":"Role of HMGB1 in regulation of STAT3 expression in CD4 + T cells from patients with aGVHD after allogeneic hematopoietic stem cell transplantation[J]","volume":"161","author":"Xu","year":"2015","journal-title":"Clin. Immunol."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822000652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822000652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:48:15Z","timestamp":1758736095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384822000652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":37,"alternative-id":["S0049384822000652"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2022.02.021","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HMGB1 is increased in patients with immune thrombocytopenia and negatively associates with Tregs","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2022.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}